Vitamin D3 for Life

Live Enlightened

Physiology

Placental Vitamin D Metabolism and Transport: Study Summary

Previous related pagePlacental Vitamin D Metabolism and Transport: Full Evidence ReviewNext related pagePlacental Vitamin D Metabolism and Transport: Full Evidence Review
Study at a glance

What question did the studies ask?

How does the placenta take up and change vitamin D compounds? Researchers studied human placentas after delivery, early placental cells and samples from a pregnancy trial.

What did they find?

The placenta took up and changed vitamin D compounds in laboratory experiments. Higher vitamin D3 intake in the pregnancy trial raised 25-hydroxyvitamin D in umbilical-cord blood. This is a form that cells can change into active hormone. The researchers did not detect an overall difference in activity of the five placental genes tested.

What does this mean?

The placenta helps regulate vitamin D locally. A higher blood result, a change in a cell and better fetal health are different outcomes. These studies do not show that increasing maternal vitamin D improves fetal development.

What are the limits?

Some experiments were very small. Labelled active hormone was detected in only one of the placentas tested with labelled compounds. Two reports may share participants. Pregnancy stages, tissue preparations and vitamin D forms differed. The evidence does not establish a personal pregnancy dose or blood target.

Read the full article below ↓

The placenta can take up and change vitamin D compounds. This review asks how those processes relate to the mother’s blood supply and the vitamin D reaching the fetus. It compares experiments in human placentas and placental cells with samples from a pregnancy trial. The studies support local regulation, but they do not establish that increasing maternal vitamin D improves fetal development. Read the detailed assessment, Placental Vitamin D Metabolism and Transport: Full Evidence Review.

What was studied?

Most vitamin D blood tests measure 25-hydroxyvitamin D. This is a form that some cells can change into calcitriol, the active hormone. Enzymes are proteins that help chemical reactions happen. Some help produce active vitamin D; others help break down vitamin D compounds. For carrier background, see Vitamin D Transport Proteins.

Researchers kept the blood-vessel pathways working in placentas after delivery and supplied labelled 25-hydroxyvitamin D3, a form that cells can change into active hormone, so they could follow it. Other studies examined early placental cells and how active certain genes were. A pregnancy trial assigned women by chance to different daily amounts of vitamin D3. It measured placental genes and vitamin D in blood from the umbilical cord. The general processing background is Vitamin D Metabolism at the Cellular Level.

What did the studies find?

The experiments in delivered placentas supported uptake, chemical changes and transfer of vitamin D compounds. They were small. Labelled active hormone was detected in one placenta. The findings do not establish how quickly active hormone reaches the fetal side across all samples.

Other experiments showed that a chemical change to DNA could reduce activity of a gene involved in vitamin D breakdown. This does not mean that the placenta cannot break down vitamin D. Some early placental cells moved through a laboratory barrier more readily after exposure to vitamin D compounds. That does not establish better development in pregnancy.

In the GRAVITD trial samples, the higher daily amount of vitamin D3 produced higher 25-hydroxyvitamin D in umbilical-cord blood. The researchers did not detect an overall difference in how active the five measured placental genes were. Gene activity, transport speed and clinical health are different outcomes. For receptor background, without assuming measured gene activity proves a functional response, see Vitamin D Receptors.

What does this mean?

The placenta is an active part of vitamin D handling. However, a higher blood concentration does not prove that a particular transport pathway has improved. A cell response does not prove better fetal health.

What are the main limits?

The studies used different stages of pregnancy, tissue preparations and vitamin D forms. Some experiments were very small. Two reports used potentially overlapping placental samples and should not be treated as fully independent confirmation. The pregnancy trial’s placental samples came from pregnancies selected because they had no major complications of the kinds excluded by the study.

The evidence does not establish an individual pregnancy dose, a blood target or a proven effect on how the mother’s immune system tolerates the fetus. The daily amounts tested describe the research.

Sources

Related reading

Library

Diverse Effects of Combinations of Maternal-Neonatal VDR Polymorphisms and 25-Hydroxyvitamin D Concentrations on Neonatal Birth Anthropometry: Functional Phenocopy Variability Dependence, Highlights the Need for Targeted Maternal 25-Hydroxyvitamin D Cut-Offs during Pregnancy

The aim of this study was to evaluate the combined effect of maternal and neonatal VDR polymorphisms (ApaI, TaqI, BsmI, FokI, Tru9I) and different maternal and neonatal 25(OH)D cut-offs on neonatal birth anthropometry.

Original paper ↗Read more →

Original sources

Source

Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface

Published in Novakovic B et al (2009).

Publication details

Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. Novakovic B et al. 2009. The Journal of biological chemistry. Volume 284(22); pages/article 14838-14848. DOI: 10.1074/jbc.m809542200.

Read more →